


(+/-)-2-(N-Phenethyl-N-1'-[¹¹C]propyl)amino-5-hydroxytetralin [¹¹C]PPHT

Kam Leung, PhD¹

Created: August 16, 2006; Updated: February 4, 2008.

Chemical name:	(+/-)-2-(N-Phenethyl-N-1'-[¹¹ C]propyl)amino-5-hydroxytetralin	
Abbreviated name:	[¹¹ C]PPHT	
Synonym:		
Agent Category:	Compound	
Target:	D ₂ dopamine receptors	
Target Category:	Receptor binding	
Method of detection:	PET	
Source of signal:	¹¹ C	
Activation:	No	
Studies:	<ul style="list-style-type: none"> <i>In vitro</i> Rodents Non-human primates 	Click on the above structure for additional information in PubChem .

Background

[[PubMed](#)]

Dopamine, a neurotransmitter, plays an important role in the mediation of movement, cognition, and emotion (1, 2). Dopamine receptors are involved in the pathophysiology of neuropsychiatric diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and schizophrenia (3). Five subtypes of dopamine receptors, D₁ through D₅, have been well characterized pharmacologically and biochemically (4). These five dopamine receptor subtypes are classified into two subfamilies: D₁-like (D₁ and D₅) and D₂-like (D₂, D₃, and D₄). D₁-like and D₂-like receptors exert synergistic as well as opposite effects at both the biochemical and overall system

levels. Most striatal D₁ and D₂ receptors are localized postsynaptically on caudate-putamen neurons and to a lesser extent presynaptically on nigrostriatal axons.

Dopamine receptors are G-protein-coupled receptors that exist in high- and low-affinity states with respect to agonist binding. The two states are inter-convertible. In the high-affinity state, dopamine receptors are coupled to G-proteins, whereas in the low-affinity state they are not. Dopamine has a dissociation constant (K_d) of 7 nM for the high-affinity state (K_{high}) and a K_d of 1,720 nM for the low-affinity state (K_{low}) (5). Under physiologic conditions, dopamine binds predominately to receptors in the high-affinity state. The high-affinity state was suggested to be the functional form of the dopamine receptors (6).

Substituted benzamides, such as sulpiride, raclopride, and iodobenzamide, are specific ligands with only moderate affinity for the D₂ receptors, making study of extrastriatal D₂ receptors difficult (7-9). In binding studies, [¹²³I]epidepride, an analog of isoremoxipride, was found to have high potency and low nonspecific binding, and to be selective for striatal and extrastriatal D₂ receptors (10). Epidepride exhibits marginal binding to D₄ receptors, with little affinity for other known neurotransmitter receptors. (S)-N-((1-Allyl-2-pyrrolidinyl)methyl)-5-(3-[¹⁸F]fluoropropyl)-2,3-dimethoxybenzamide ([¹⁸F]fallypride), an analog of epidepride, was found to be a selective high-affinity antagonist of D_{2/3} receptors (11), and in positron emission tomography (PET) *in vivo* studies (12-14) it identified extrastriatal D_{2/3} receptors. However, none of these antagonists distinguishes between the high- and low-affinity states of the D₂ receptors. (-)-N-[¹¹C]Propyl-norapomorphine ([¹¹C]NPA) and [¹¹C](+)-4-N-propyl-,3,4a,5,6,10b-hexahydro-2H-naphth[1,2-b][1,4]oxazin-9-ol ([¹¹C](+)-PHNO) have been developed as radiolabeled dopamine agonists for the non-invasive study of the high-affinity state of the D_{2/3} receptors in the brain.

Various hydroxytetralin analogs with different binding affinities for the D₂ receptors have been developed as agonist radiotracers (15). (+/-)-2-(N-Phenethyl-N-1'-[¹¹C]propyl)amino-5-hydroxytetralin ([¹¹C]PPHT) is being evaluated as a PET agent for the high-affinity state of D_{2/3} receptors.

Synthesis

[PubMed]

Shi et al. (15) reported a two-step synthesis of [¹¹C]PPHT in which [¹¹C]propionyl chloride was reacted with 5-hydroxy-2-[N-(2-phenethyl)amino]tetralin and followed by LiAlH₄ reduction, with a radiochemical yield of 5–10% (based on [¹¹C]CO₂ at the end of bombardment) and an average specific activity of 9–37 GBq/μmol (250–1,000 mCi/μmol) at end of synthesis after purification by high-performance liquid chromatography.

[¹¹C]Propionyl chloride was prepared by reacting [¹¹C]CO₂ with ethylmagnesium bromide, followed by reaction with phthaloyl chloride. Total synthesis time was 60–75 min.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

In a binding study of dopamine receptors in membranes of the rat striatum with [³H]spiperone, PPHT had an IC₅₀ of 0.65 nM (15). *In vitro* autoradiography studies of rat brain slices indicated selective binding of [¹¹C]PPHT to the striata, which was completely inhibited by co-incubation with 10 μM sulpiride. Gpp(NH)p decreased the striatum/cerebellum ratio from 2.0 to 1.1 by converting the high-affinity state to the low-affinity state. There was significant nonspecific binding in the cortex.

Animal Studies

Rodents

[PubMed]

Biodistribution studies in rats showed a marked accumulation of the tracer in the striata within the first 2 min [1.2% injected dose per gram (ID/g)], followed by a decrease of radioactivity to 0.5% ID/g at 30 min and 0.2% ID/g at 60 min (16). The striatum/cerebellum ratios were 1.27 at 2 min, 1.52 at 30 min, and 1.42 at 60 min after injection. Haloperidol pretreatment (1 mg/kg, 15 min before radiotracer injection) effectively reduced specific binding of [¹¹C]PPHT to the striatum with some residual binding relative to the cerebellum at 30 min. Little inhibition was seen in the cerebellum. [¹¹C]PPHT thus displays uptake and washout kinetics characteristic of reversible radiotracers.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

Mukherjee et al. (16) showed selective accumulation (0.03% ID/ml) in the striata of two rhesus monkeys with striatum/cerebellum ratios of 1.5 at 30 min and 1.4 at 60 min after injection of 26–93 MBq (0.7–2.5 mCi) of [¹¹C]PPHT. Thalamus/cerebellum ratios were 1.3 at 30 min and 1.2 at 60 min. However, there was a substantial nonspecific binding in the cortex and cerebellum. The authors suggested that the use of the more active S-isomer may provide higher striatum/cerebellum and thalamus/cerebellum ratios.

Human Studies

[PubMed]

No relevant publication is currently available.

References

1. Carbon M., Ghilardi M.F., Feigin A., Fukuda M., Silvestri G., Mentis M.J., Ghez C., Moeller J.R., Eidelberg D. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. *Hum Brain Mapp.* 2003;19(3):197–211. PubMed PMID: 12811735.
2. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. *Trends Neurosci.* 1996;19(10):417–22. PubMed PMID: 8888518.
3. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Tourtellotte W.W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. *Neuropsychopharmacology.* 1987;1(1):5–15. PubMed PMID: 2908095.
4. Stoof J.C., Kebabian J.W. Two dopamine receptors: biochemistry, physiology and pharmacology. *Life Sci.* 1984;35(23):2281–96. PubMed PMID: 6390056.
5. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. *Nature.* 1991;350(6319):614–9. PubMed PMID: 1826762.

6. Sibley D.R., De Lean A., Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. *J Biol Chem.* 1982;257(11):6351–61. PubMed PMID: 6176582.
7. Gehlert D.R., Wamsley J.K. Autoradiographic localization of [3H]sulpiride binding sites in the rat brain. *Eur J Pharmacol.* 1984;98(2):311–2. PubMed PMID: 6714315.
8. Lidow M.S., Goldman-Rakic P.S., Rakic P., Innis R.B. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. *Proc Natl Acad Sci U S A.* 1989;86(16):6412–6. PubMed PMID: 2548214.
9. Brucke T., Tsai Y.F., McLellan C., Singhanyom W., Kung H.F., Cohen R.M., Chiueh C.C. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. *Life Sci.* 1988;42(21):2097–104. PubMed PMID: 3260318.
10. Kessler R.M., Ansari M.S., Schmidt D.E., de Paulis T., Clanton J.A., Innis R., al-Tikriti M., Manning R.G., Gillespie D. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. *Life Sci.* 1991;49(8):617–28. PubMed PMID: 1830917.
11. Mukherjee J., Yang Z.Y., Das M.K., Brown T. Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. *Nucl Med Biol.* 1995;22(3):283–96. PubMed PMID: 7627142.
12. Grunder G., Landvogt C., Vernaleken I., Buchholz H.G., Ondracek J., Siessmeier T., Hartter S., Schreckenberger M., Stoeter P., Hiemke C., Rosch F., Wong D.F., Bartenstein P. and , The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. *Neuropsychopharmacology.* 2005.
13. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Collins D. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. *Brain Res.* 2005;1032(1-2):77–84. PubMed PMID: 15680944.
14. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., Meltzer H.Y. Occupancy of striatal and extrastriatal dopamine d(2)/d(3) receptors by olanzapine and haloperidol. *Neuropsychopharmacology.* 2005;30(12):2283–9. PubMed PMID: 16123775.
15. Shi B., Narayanan T.K., Yang Z.Y., Christian B.T., Mukherjee J. Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N-1'-11C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D-2 receptors. *Nucl Med Biol.* 1999;26(7):725–35. PubMed PMID: 10628551.
16. Mukherjee J., Narayanan T.K., Christian B.T., Shi B., Yang Z.Y. Binding characteristics of high-affinity dopamine D2/D3 receptor agonists, 11C-PPHT and 11C-ZYY-339 in rodents and imaging in non-human primates by PET. *Synapse.* 2004;54(2):83–91. PubMed PMID: 15352133.